Free Trial

Tourmaline Bio (TRML) Competitors

Tourmaline Bio logo
$19.16 +0.16 (+0.84%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TRML vs. INDV, APGE, IRON, BHC, BEAM, ARQT, BHVN, SDGR, EWTX, and JANX

Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Indivior (INDV), Apogee Therapeutics (APGE), Disc Medicine (IRON), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

Tourmaline Bio vs.

Tourmaline Bio (NASDAQ:TRML) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

In the previous week, Tourmaline Bio and Tourmaline Bio both had 7 articles in the media. Indivior's average media sentiment score of 1.35 beat Tourmaline Bio's score of 1.21 indicating that Indivior is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tourmaline Bio
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Indivior
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Indivior has higher revenue and earnings than Tourmaline Bio. Indivior is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$42.12M-$3.21-6.11
Indivior$1.17B1.60$2M-$0.31-43.67

Tourmaline Bio has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Tourmaline Bio's return on equity of -20.97% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -20.97% -20.56%
Indivior -3.96%-241.73%15.09%

Tourmaline Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 151.51%. Indivior has a consensus target price of $15.00, indicating a potential upside of 10.81%. Given Tourmaline Bio's higher possible upside, equities research analysts plainly believe Tourmaline Bio is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Indivior
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Tourmaline Bio received 13 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 96.00% of users gave Tourmaline Bio an outperform vote.

CompanyUnderperformOutperform
Tourmaline BioOutperform Votes
24
96.00%
Underperform Votes
1
4.00%
IndiviorOutperform Votes
11
100.00%
Underperform Votes
No Votes

Summary

Tourmaline Bio beats Indivior on 9 of the 17 factors compared between the two stocks.

Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRML vs. The Competition

MetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$503.17M$3.11B$5.60B$8.63B
Dividend YieldN/A1.59%5.27%4.19%
P/E Ratio-6.9533.6327.3220.13
Price / SalesN/A476.07411.80160.09
Price / CashN/A168.6838.2534.64
Price / Book1.953.497.154.74
Net Income-$42.12M-$72.35M$3.23B$247.80M
7 Day Performance4.73%8.24%3.47%2.70%
1 Month Performance29.99%22.80%12.95%10.03%
1 Year Performance25.58%-16.01%32.16%15.42%

Tourmaline Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRML
Tourmaline Bio
2.1629 of 5 stars
$19.16
+0.8%
$49.33
+157.5%
+25.0%$491.23MN/A-6.7844Positive News
Analyst Revision
INDV
Indivior
1.984 of 5 stars
$12.46
-3.1%
$15.00
+20.4%
-19.3%$1.72B$1.17B-35.601,164Positive News
APGE
Apogee Therapeutics
2.0557 of 5 stars
$36.33
-0.8%
$94.60
+160.4%
-4.3%$1.67BN/A-15.0191
IRON
Disc Medicine
1.8605 of 5 stars
$47.73
+2.2%
$98.80
+107.0%
+33.6%$1.65BN/A-11.9930Positive News
Analyst Forecast
Insider Trade
Analyst Revision
BHC
Bausch Health Companies
4.5745 of 5 stars
$4.49
-1.0%
$7.42
+65.4%
-19.5%$1.64B$9.73B-37.3719,900Positive News
BEAM
Beam Therapeutics
3.0457 of 5 stars
$16.19
+2.3%
$48.75
+201.1%
-25.9%$1.63B$63.58M-9.20510Analyst Revision
ARQT
Arcutis Biotherapeutics
2.0066 of 5 stars
$13.48
+3.4%
$18.80
+39.5%
+84.2%$1.61B$212.82M-7.53150Positive News
BHVN
Biohaven
2.7911 of 5 stars
$15.62
+5.4%
$59.46
+280.8%
-52.2%$1.59BN/A-1.67239Analyst Revision
High Trading Volume
SDGR
Schrödinger
1.5661 of 5 stars
$21.69
+0.3%
$32.80
+51.2%
+22.4%$1.59B$230.49M-9.27790
EWTX
Edgewise Therapeutics
3.1058 of 5 stars
$14.69
+2.9%
$40.22
+173.8%
-9.8%$1.55BN/A-9.7960
JANX
Janux Therapeutics
1.5855 of 5 stars
$25.01
+5.1%
$95.25
+280.8%
-39.5%$1.48B$9.34M-21.3830Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:TRML) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners